福里与拉德纳律师事务所合伙人米歇尔·西姆金在近期医疗保健与生命科学网络研讨会中的见解,被《PharmaVoice》文章 《肥胖领域并购升温,制药企业或将"被机遇蒙蔽双眼"》所引用。
在2025年9月福莱公司举办的"GLP-1药物焦点:趋势、需求与未来展望"网络研讨会上,西姆金重点强调了GLP-1药物的成功。"它们具有惊人的疗效,"她特别指出。
关于GLP-1市场的未来走向,西姆金指出这类药物还能通过帮助患者达到BMI标准,从而"提高患者接受手术和移植的资格条件"。她补充道,制药公司正致力于开发联合用药方案——将GLP-1与其他药物组合,或研发更强效的产品,包括双重和三重激动剂。
相关新闻
December 24, 2025
In the News
Kyle Faget on HHS Gender-Affirming Care Declaration – Impact is 'Enormous'
Foley & Lardner LLP partner Kyle Faget commented on the recent Department of Health and Human Services declaration rejecting gender-affirming care in the STAT News article, “Nineteen states, D.C. sue HHS over gender-affirming care crackdown."
December 22, 2025
In the News
Monica Call in Law.com Leadership Spotlight – 'I see my role as both coach and advocate'
Foley & Lardner LLP partner Monica Call reflects on leadership, mentorship, and strategy in Law.com's "How I Made It Office Managing Partner" series.
December 18, 2025
In the News
Kyle Faget Weighs in on HHS Proposed Rule Limiting Gender-Affirming Care
Foley & Lardner LLP partner Kyle Faget commented on a recent proposal from the U.S. Department of Health and Human Services in the Law360 article, “HHS Proposes Hospital Ban On Gender Care For Minors.”